| dc.description.abstract | Taking a glucocorticoid medication (sometimes called corticosteroids) for treatment
of inflammatory arthritis or other health problem may weaken the bones, in turn, can lead
to osteoporosis. Glucocorticoid medicines have both direct and indirect effects on bone
tissue that lead to bone loss. Randomized placebo-controlled clinical trials have
demonstrated that the amino-bisphosphonates risedronate and alendronate, both potent
anti-resorptive agents, can prevent and treat glucocorticoid-induced osteoporosis. The aim
of this research is develop an experimental model for evaluating the therapeutic effects of
drugs to treat osteoporosis.
The research was performed to study on parameters related to glucocorticoidinduced osteoporosis in mice i.e. bone weight, bone length, phosphorus contents, plasma
alkaline phosphatase, and bone morphology. Methylprednisolone, a synthetic glucocorticoid
was used to induce osteoporosis. Methylprednisolone was subcutaneously injected in the
doses of 5, 10 and 20 mg/kg.
The revealed results demonstrated that glucocorticoid decreased bone calcium and
phosphorus contents, plasma alkaline phosphatase, and induced osteoporosis in bone
morphological images, markedly after four weeks subcutaneous injection of
methylprednisolone. Treatment of alendronate (oral dose of 2.5 mg/kg mouse body weight)
for 4 weeks after methylprednisolone restored the changes in parameters related to
osteoporosis to the normal values.
In this research, the osteoporosis mouse model was created by using hormonal
intervention – pharmaceutical with the corticosteroid in long term and treated with
bisphosphonates – alendronate.
Key words: Osteoporosis, glucocorticoids, alendronate. | en_US |
